This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Mysimba
  • /
  • Cardiovascular Outcomes Study of Naltrexone SR/Bup...
Clinical trial

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Read time: 3 mins
Last updated:1st Jun 2012
Identifier: NCT01601704

The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese subjects who are at a higher risk of having these events because they have diabetes and/or other cardiovascular risk factors.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 8910 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR
Study Start Date: June 2012
Actual Primary Completion Date: August 2015
Actual Study Completion Date: August 2015

Arms:
- Experimental:
NB32
- Placebo Comparator: PBO

Category Value
Date last updated at source 2017-02-27
Study type(s) Interventional
Expected enrolment 8910
Study start date 2012-06-01
Estimated primary completion date 2015-08-01

View full details